Dr. Sana Salih and colleagues have published a new paper, Dexrazoxane Diminishes Doxorubicin-Induced Acute Ovarian Damage and Preserves Ovarian Function and Fecundity in Mice, on fertility preservation in young mice treated with chemotherapies. Teresa Woodruff says that ‘fertoprotective therapies are the most important next step in research to protect ovarian function in women with cancer.’ Dr. Salih said that the most important points in the paper include ‘The fertoprotective drug, dexrazoxane (Dexra) pre-administration prevented ovarian damage and preserved fertility in pre-pubescent mice treated with doxorubicin (DXR) chemotherapy.
The final day of the Oncofertility Conference was high-yield for attendees, who were fortunate to hear about best practices in oncofertility from the experts at Cincinnati Children’s Hospital Medical Center (CCHMC). Please find their efficient and thorough powerpoint uploaded above. Thank you to Drs. Breech, Hoefgen, Burns and their entire team!
The final day of the Oncofertility Conference was high-yield for attendees, who were fortunate to hear about best practices in oncofertility from the experts at Cincinnati Children's Hospital Medical Center (CCHMC). Please find their efficient and thorough powerpoint uploaded above. Thank you to Drs. Breech, Hoefgen, Burns and their entire team!
We’re excited to co-host an event this evening with Critical Mass, a community-powered advocacy organization empowered to transform the care and treatment of young adults with cancer. Together we’re hosting a meet-and-greet to exchange good conversation and ideas.
Look forward to seeing you at 303 E Superior Street this evening!
Dr. Hayes-Lattin gave a stimulating lecture on the status of insurance coverage for fertility preservation and what we can do as healthcare providers, researchers and advocates to allow our patients to receive oncofertility coverage. Up to 60% of cancer survivors are at risk for iatrogenic infertility related to their cancer treatments and concern for infertility is second only to mortality concern among survivors. We learned that Medicaid distinguishes medically-indicated procedures (e.g.
After hearing about issues with sexual function in female young adult cancer survivors, Dr. Meacham shared with us the special issues in young adult male cancer survivors. She discussed how sexual function includes both physical and emotional components and has a key role in determining quality of life. Dr.
Dr. Sana Salih and colleagues have published a new paper, Dexrazoxane Diminishes Doxorubicin-Induced Acute Ovarian Damage and Preserves Ovarian Function and Fecundity in Mice, on fertility preservation in young mice treated with chemotherapies. Teresa Woodruff says that ‘fertoprotective therapies are the most important next step in research to protect ovarian function in women with cancer.’ Dr. Salih said that the most important points in the paper include ‘The fertoprotective drug, dexrazoxane (Dexra) pre-administration prevented ovarian damage and preserved fertility in pre-pubescent mice treated with doxorubicin (DXR) chemotherapy.
